![Spiros D. Garbis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Spiros D. Garbis
Vorstandsvorsitzender bei Proteas Bioanalytics, Inc.
Profil
Spiros D.
Garbis was the founder of Proteas Bioanalytics, Inc. and held the titles of President, CEO, CTO & Director.
Aktive Positionen von Spiros D. Garbis
Unternehmen | Position | Beginn |
---|---|---|
Proteas Bioanalytics, Inc.
![]() Proteas Bioanalytics, Inc. Internet Software/ServicesTechnology Services Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Proteas Bioanalytics, Inc.
![]() Proteas Bioanalytics, Inc. Internet Software/ServicesTechnology Services Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation. | Technology Services |